Condition

Large B-cell Lymphoma clinical trials and research

• 37Clinical trials
• 24NIH research projects
• 21Countries

Newest Large B-cell Lymphoma clinical trials

All recruiting trials (37)

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

• Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

  This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07478848

• Lisocabtagene maraleucel to prevent recurrence of large B‑cell lymphoma after first-line therapy

  This trial tests whether a CAR T-cell treatment called liso-cel can prevent return of large B‑cell lymphoma in adults who are in complete remission after first-line chemoimmunotherapy but still have detectable lymphoma DNA.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07316010

• Glofitamab plus PD‑1 antibody and lenalidomide for relapsed/refractory TP53‑aberrant large B‑cell lymphoma

  This trial will test whether combining glofitamab with a PD‑1 antibody and lenalidomide can help adults with relapsed or refractory large B‑cell lymphoma that has TP53 mutations or deletions.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07240194

• Predictors of response to CD19 CAR-T therapy in relapsed/refractory large B‑cell lymphoma

  This study will see if clinical features, tumor biology, and immune cell changes can predict who responds to CD19 CAR‑T therapy for relapsed/refractory large B‑cell lymphoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07236203

• AZD0486 with short-course R-mini-CHOP for older or unfit people with large B‑cell lymphoma

  This tests whether two cycles of R-mini-CHOP followed by AZD0486 work as well and cause fewer side effects than six cycles of R-mini-CHOP for people aged 80+ or 65–79 who are unfit with newly diagnosed large B‑cell lymphoma.

  Recruiting at 29 sites Phase 3 AstraZeneca · Clayton and 81 other locations · NCT07215585

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Epcoritamab with response-adaptive escalation for first-relapse large B‑cell lymphoma

  This will try epcoritamab alone for three cycles and, for some patients, switch to epcoritamab plus tafasitamab and lenalidomide to see if it improves response in people with first-relapse large B‑cell lymphoma.

  Recruiting at 19 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Seville, Andalusia and 18 other locations · NCT07126236

• NT-I7 (efineptakin alfa) given after Yescarta or Breyanzi for relapsed/refractory large B‑cell lymphoma

  This trial tests whether giving NT-I7, a long‑acting IL‑7, after CAR T‑cell therapy (Yescarta or Breyanzi) helps people with relapsed/refractory large B‑cell lymphoma recover T cells and improve outcomes.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07052305

• Real-world outcomes with glofitamab for large B-cell lymphoma

  This project looks at how well glofitamab works and how safe it is for adults in France with relapsed or refractory large B‑cell lymphoma who were treated through the expanded access program.

  Recruiting at 30 sites The Lymphoma Academic Research Organisation · Argenteuil and 29 other locations · NCT06994169

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

• Using Tafasitamab and Lenalidomide for Large B-cell Lymphoma after CAR-T Therapy

  This study is testing if the combination of tafasitamab and lenalidomide can help people with Large B-cell Lymphoma who still have cancer after CAR-T therapy.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06760156

• UB-VV400 plus rapamycin for relapsed or refractory large B‑cell lymphoma

  This will test UB‑VV400 alone and together with rapamycin to see if it's safe and helps adults with relapsed or refractory large B‑cell lymphoma, including people who have had CAR‑T therapy.

  Recruiting Phase 1 Nanjing IASO Biotechnology Co., Ltd. · Nanjing and 1 other locations · NCT06743503

• Using BHB with CAR-T therapy for lymphoma treatment

  This study is testing if taking a supplement called BHB while getting CAR-T therapy for large B-cell lymphoma can be safe and help improve the treatment's effects on the body.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06610344

• Evaluating AZD0486 for treating mature B-cell cancers

  This study is testing a new treatment called AZD0486 to see if it can help people with certain types of mature B-cell cancers feel better and improve their health.

  Recruiting at 56 sites Phase 1/2 AstraZeneca · Boston, Massachusetts and 65 other locations · NCT06564038

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Using cema-cel to treat patients with large B-cell lymphoma who have minimal residual disease after first-line therapy

  This study is testing if a new CAR T-cell therapy called cema-cel can help adults with large B-cell lymphoma who still have some cancer left after their first treatment feel better compared to just being monitored.

  Recruiting at 84 sites Phase 2 Allogene Therapeutics · Gilbert, Arizona and 85 other locations · NCT06500273

• Treatment of relapsed large B-cell lymphoma with WZTL-002 CAR T-cells

  This study is testing a new CAR T-cell therapy called WZTL-002 to see if it can help adults with relapsed large B-cell lymphoma that hasn't worked with standard chemotherapy.

  Recruiting at 3 sites Phase 2 Malaghan Institute of Medical Research · Auckland, Auckland and 2 other locations · NCT06486051

• CAR T cell therapy for relapsed large B-cell lymphoma

  This study is testing a new CAR T cell therapy to see if it can help adults with relapsed large B-cell lymphoma who haven't responded to previous treatments.

  Recruiting Phase 2 Shanghai Ming Ju Biotechnology Co., Ltd. · Tianjin, Tianjin Municipality · NCT06479356

• GFH009 combined with Zanubrutinib for treating relapsed DLBCL

  This study is testing if a new treatment combining GFH009 and Zanubrutinib can help people with relapsed or hard-to-treat diffuse large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Nanning and 1 other locations · NCT06375733

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• Using CAR T cells to treat certain types of B cell lymphomas

  This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06340737

• Evaluating Zanubrutinib and Tislelizumab for Progressive Lymphoma After CAR-T Therapy

  This study is testing whether a combination of zanubrutinib and tislelizumab can help people with large B-cell lymphoma who have not responded well after CAR-T therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06167785

• Ablative radiation before CAR-T therapy for high-risk lymphoma

  This study is testing if giving radiation therapy before CAR T-cell treatment can help people with high-risk lymphoma have better results.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06104592

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

• Treatment of B-cell malignancies with ALETA-001

  This study is testing a new treatment called ALETA-001 to see if it can help people with relapsed non-Hodgkin lymphoma who didn't respond well to previous therapies.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Birmingham and 6 other locations · NCT06045910

• Combining Epcoritamab with Rituximab-mini CVP for Older Patients with Newly Diagnosed Large B-cell Lymphoma

  This study is testing if adding a new drug called epcoritamab to the standard treatment for older patients with newly diagnosed large B-cell lymphoma can improve their chances of recovery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06045247

• Training for oncologists to improve communication with lymphoma patients

  This study tests a new training program for oncologists to help them communicate better with patients who have diffuse large B-cell lymphoma about their diagnosis and care options.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT05940272

• Combining stem cell collection with CAR T-cell therapy for blood cancers

  This study is testing if collecting stem cells from patients with blood cancers can safely be combined with CAR T-cell therapy to improve treatment outcomes.

  Recruiting Phase 1 Cedars-Sinai Medical Center · Los Angeles, California · NCT05887167

• Treatment of aggressive large B-cell lymphoma with LYL314

  This study is testing a new CAR T-cell therapy called LYL314 to see if it can effectively treat aggressive large B-cell lymphoma in different groups of patients.

  Recruiting at 35 sites Phase 1/2 Lyell Immunopharma, Inc. · Irvine, California and 34 other locations · NCT05826535

• Combining Acalabrutinib with R-miniCHOP for older adults with untreated diffuse large B-cell lymphoma

  This study tests if adding Acalabrutinib to the usual treatment for older adults with untreated diffuse large B-cell lymphoma can help them live longer without their cancer getting worse.

  Recruiting at 9 sites Phase 3 Universität des Saarlandes · Homburg, Saarland and 16 other locations · NCT05820841

• CAR T-cell therapy for relapsed B-lineage leukemia and lymphoma

  This study is testing if a new CAR T-cell therapy can be safely given to patients with relapsed B-lineage leukemia and lymphoma to see how well it works.

  Recruiting at 2 sites Phase 2 KK Women's and Children's Hospital · Singapore and 1 other locations · NCT05648019

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Using loncastuximab tesirine to treat large B-cell lymphoma after CAR T-cell therapy

  This study is testing if a new treatment called loncastuximab tesirine can help people with large B-cell lymphoma who haven't fully responded to CAR T-cell therapy feel better and stay in remission.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05464719

• Long-term follow-up of gene-edited immune cell therapy for lymphoma

  This study is checking how safe and effective a gene-edited immune cell therapy is for people with lymphoma who received the treatment in the past.

  Recruiting at 5 sites Pell Bio-Med Technology Co., Ltd. · Kaohsiung, Taiwan and 4 other locations · NCT05377307

NIH-funded research (24)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma

  A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403920

• Cardioprotective treatment choices for DLBCL patients at risk of heart damage

  Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11402640

• Translating Genomics to Practice to Overcome Disparities in DLBCL

  A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11401446

• From pathogenesis to new targets for treating diffuse large B-cell lymphoma

  A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11377580

• Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma

  A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.

  NIH research University of Chicago · Chicago, United States · NIH-11353865

• Lowering c-Myc to treat aggressive large B‑cell lymphoma

  This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11321531

• EBV-related lymphoma in people with immune deficiency: understanding what drives the disease

  A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11300775

• Computer models to improve combination treatments for diffuse large B‑cell lymphoma

  This project builds computer simulations to help design better combination drug regimens for people with diffuse large B‑cell lymphoma.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11260268

• Blocking EGR1 to treat aggressive diffuse large B‑cell lymphoma

  This project tests blocking a protein called EGR1 to help people with the aggressive ABC type of diffuse large B‑cell lymphoma who don't respond well to standard therapy.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11250037

• A new chemotherapy option for diffuse large B‑cell lymphoma

  This project develops a new chemotherapy drug intended to kill diffuse large B‑cell lymphoma cells, including cancers that don't respond to current treatment.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11229618

• EBV-positive diffuse large B-cell lymphoma in people with weakened immune systems

  Researchers will compare tumor and virus features in people with EBV-positive diffuse large B-cell lymphoma who have weakened immune systems from HIV or medical treatments to better link biology to health outcomes.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11222776

• Understanding how EBV affects lymphoma in patients with weakened immune systems

  This study is looking at how the Epstein-Barr virus affects a type of cancer called diffuse large B-cell lymphoma, especially in people with weakened immune systems, like those with HIV, to help find better ways to diagnose and treat this illness.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11222775

• New Ways to Treat Diffuse Large B Cell Lymphoma

  This project explores the genetic differences in diffuse large B cell lymphoma to discover new treatment options for patients.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11158782

• Understanding how genes affect immune responses in lymphoma treatment

  This study is looking at how the immune system interacts with diffuse large B cell lymphoma (DLBCL) to find out which genetic traits might help predict how well patients will respond to immunotherapy, so that treatments can be better tailored for those whose cancer has come back or hasn’t responded to other treatments.

  NIH research University of Chicago · Chicago, United States · NIH-11079518

• Using blood tests to tailor treatment for lymphoma patients

  This study is looking at how a simple blood test can help doctors tailor treatment for people newly diagnosed with diffuse large B-cell lymphoma, so they can get the right amount of therapy to reduce side effects while still being effective.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11045782

• Targeting a protein involved in aggressive B-cell lymphoma

  This study is looking at a type of aggressive lymphoma called double and triple-hit lymphomas to understand how a protein named TBL1X affects the disease, with the goal of finding better treatments to help patients live longer and healthier lives.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11042777

• Developing computer models for combination therapy in aggressive lymphomas

  This study is looking at how different combinations of drugs can work together to treat Diffuse Large B-Cell Lymphoma (DLBCL) better, using computer simulations to understand how these treatments might affect different patients and their unique tumors.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11017031

• A new treatment for diffuse large B-cell lymphoma

  This study is testing a new treatment for diffuse large B-cell lymphoma (DLBCL) using a special compound that has shown promise in lab tests, and it's designed for patients who haven't had success with current therapies.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11001979

• Targeting genetic changes in aggressive lymphoma for better treatment

  This study is looking at how certain changes in genes on chromosome 18 can make diffuse large B-cell lymphoma (DLBCL) more aggressive, and it aims to create personalized treatments using new medicines that target these genetic markers to help improve outcomes for patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10986115

• Investigating EGR1 signaling pathways in aggressive lymphoma

  This study is looking at a tough type of lymphoma called ABC DLBCL to figure out why some treatments don’t work and hopes to find new ways to help patients who haven’t had success with current therapies.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10982513

• Investigating new treatment targets for diffuse large B cell lymphoma

  This study is looking at a tough type of cancer called diffuse large B cell lymphoma (DLBCL) to find new ways to treat it by exploring the genes that might be causing the cancer to behave differently, and it’s for patients who are facing challenges with their current treatments.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10928175

• Understanding how BCL10 mutations affect treatment resistance in a type of lymphoma

  This study is looking at how certain changes in a gene called BCL10 might make it harder for people with diffuse large B cell lymphoma to respond to standard treatments, with the goal of finding better ways to help those patients.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10894687

• Identifying biomarkers for HIV-related lymphoma in Malawi and South Africa

  This study is looking at how certain markers in tumors can help doctors better diagnose and treat HIV-related lymphoma in patients in Malawi and South Africa, aiming to improve care for those facing this challenge.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10891547

• Understanding how MYC gene activation affects diffuse large B-cell lymphoma

  This study is looking at how a gene called MYC behaves in a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find new ways to improve treatments and help doctors predict how the disease will progress for patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-10880680

Related topics

Quick answers

How many Large B-cell Lymphoma clinical trials are recruiting right now?

37, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (22 trials), China (7 trials), Australia (6 trials), Canada (4 trials), United Kingdom (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 1/2: 7, Phase 1: 6, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →